POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) is a clinical-stage radiopharmaceutical company focused on developing and commercializing radioligand therapies for oncology. The company entered the public markets through a business combination with GX Acquisition Corp. II, a blank-check vehicle sponsored by GX Clarke & Co. LLC that completed its initial public offering in 2020. The 10-Q filed on April 29, 2021 reflects POINT Biopharma's financial disclosures as the de-SPAC transaction moved toward its mid-2021 close. The company operates in the biopharmaceutical sector, with its pipeline centered on precision cancer treatment. For full filing history, sponsor data, and deal timelines on PNT and thousands of other SPAC transactions, sign up for complete access at SpacDesk.